[New York, October 28, 2019] Lifescience Dynamics, an award-winning global decision support consultancy serving the life sciences sector for over 15 years, has appointed Alfred Reszka, PhD to the newly created role of Chief Business Officer.
Dr. Reszka joins Lifescience Dynamics after a distinguished 22-year career at Merck & Co., where he most recently served as Executive Director and Head of Strategic Business Intelligence.
Lifescience Dynamics has established itself as one of the world’s leading decision support consultancies serving pharmaceutical and other life sciences firms globally. It is headquartered in London and has branch offices in New York, San Francisco and Boston. Dr. Reszka will be based in New York and will take responsibility for the next phase in the company’s growth by identifying and developing new business opportunities and shaping the company’s longer-term strategy.
"Dr. Reszka is a globally recognized leader and pioneer in the use and implementation of intelligence to support decision making on the client side,” said Lifescience Dynamics Founder and President, Rafaat Rahmani. “He brings over two decades of deep pharma industry experience and, importantly, the commercial acumen and big pharma C-suite strategies that go with it. We are delighted to welcome him to the Lifescience Dynamics family.”
As Executive Director and Head of Strategic Business Intelligence at Merck & Co., Dr. Reszka transformed the use of commercial intelligence and developed novel hypothesis-based models that helped shape strategy across Commercial, Research and Development, Business Development and Licensing functions. The influence of his efforts extended to corporate and divisional strategy development, partnering opportunity identification and strategic benchmarking.
Dr. Reszka has served as Co-Chair and Advisory Board member for the Pharma CI conference, the single largest assembly of pharmaceutical competitive intelligence executives in the world. His leadership has extended throughout the CI and BI community in both the US and Europe. He has also served as a member of the Executive Committee of the cross-industry Intelligence Leadership Forum (ILF) and has been a featured speaker for the Strategic and Competitive Intelligence Professionals (SCIP) annual conference.
Prior to his pioneering role in Strategic Business Intelligence at Merck, Dr. Reszka led research in the bone biology and osteoporosis areas at Merck Research Laboratories. He guided the effort to elucidate the FOSAMAX™ (alendronate sodium) molecular and cellular mechanism of action and that of the Nitrogen-Containing Bisphosphonate class of osteoporosis therapies. He also led drug discovery efforts focused on hormone receptors and Wnt signal transduction pathways.
Dr. Reszka earned his PhD in Cell and Structural Biology at the University of Illinois, Urbana-Champaign, where he focused on cell adhesion through the integrin receptors in collaboration with Dr. Alan (Rick) Horwitz. Dr. Reszka continued with postdoctoral research on MAP Kinase signalling in the Department of Biochemistry at the University of Washington, Seattle in collaboration with Nobel Laureates Edmond Fischer and Edwin Krebs. His primary publications in both endeavours have been cited hundreds of times.